MedTrace Logo

Study to Evaluate Efficacy and Safety of BGE-117 in the Treatment of Anemia of Aging

NCT04815603 · Status: WITHDRAWN · Phase: PHASE2 · Type: INTERVENTIONAL

Last updated 2022-05-05

No results posted yet for this study

Summary

The primary objectives of this study to evaluate the safety, tolerability and efficacy of BGE-117 in the treatment of anemia of aging in participants ≥ 65 years of age.

Conditions

Interventions

DRUG

BGE-117

Active Treatment

OTHER

Placebo

Placebo

Sponsors & Collaborators

  • BioAge Labs, Inc.

    lead INDUSTRY

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-03-22
Primary Completion
2022-04-30
Completion
2022-04-30
FDA Drug
Yes

Countries

  • Australia

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04815603 on ClinicalTrials.gov